Clinical significance of BRAF non-V600E mutations in colorectal cancer: a retrospective study of two institutions

Yoshifumi Shimada, Yosuke Tajima, Masayuki Nagahashi, Hiroshi Ichikawa, Hidehito Oyanagi, Shujiro Okuda, Kazuaki Takabe, Toshifumi Wakai

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Recent advances in next-generation sequencing have enabled the detection of BRAF V600E mutations as well as BRAF non-V600E mutations in a single assay. The present work aimed to describe the clinicopathological characteristics and clinical outcome of the BRAF non-V600E mutant-type in colorectal cancer (CRC). Patients and methods: CRC samples from 111 Stage IV patients were analyzed for somatic mutations using a 415-gene comprehensive genomic sequencing panel. Patients were classified according to BRAF status as wild-type, V600E mutant-type, or non-V600E mutant-type. Differences between clinicopathological characteristics and genetic alterations were analyzed among the three groups. Overall survival (OS) and the response to anti-EGFR therapy were also analyzed. Results: Comprehensive genomic sequencing revealed that 98 patients (88%), 7 patients (6%), and 6 patients (6%) were wild-type, V600E mutant-type, and non-V600E mutant-type, respectively. Non-V600E mutant-type tumors were frequently left-sided (83%), while V600E mutant-type tumors were frequently right-sided (86%; P = 0.025). Non-V600E mutant-type showed better OS than V600E mutant-type (P = 0.038), with no significant difference compared with wild-type tumors. The two patients with non-V600E mutations who underwent repeated metastasectomies showed no evidence of disease at final follow-up. Regarding the efficacy of anti-EGFR therapy, the patient with an I326V mutation had progressive disease (+115%) despite no genetic alterations detected in the EGFR pathway that could drive resistance, suggesting an alternate resistance mechanism. Conclusions: Non-V600E mutant-type is more likely to be left-sided and demonstrates better OS than V600E mutant-type. Further preclinical and clinical investigations are needed to clarify the role of non-V600E mutations in CRC.

Original languageEnglish
Pages (from-to)72-81
Number of pages10
JournalJournal of Surgical Research
Volume232
DOIs
Publication statusPublished - 12-2018

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint Dive into the research topics of 'Clinical significance of BRAF non-V600E mutations in colorectal cancer: a retrospective study of two institutions'. Together they form a unique fingerprint.

  • Cite this